IRIS
GATTO, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.922
Totale 4.922
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.922
Totale 4.922
Salva come PNG Salva come JPEG
Città #
Genova 3.923
Rapallo 520
Genoa 469
Bordighera 10
Totale 4.922
Salva come PNG Salva come JPEG
Nome #
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 174
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 150
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 134
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 131
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 123
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 123
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 120
Does pasireotide directly modulate skeletal muscle metabolism? 120
Hormone receptors analysis in idiopathic progressive subglottic stenosis 117
Somatostatin receptor scintigraphy in thoracic diseases 113
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 113
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 111
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 111
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 109
P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients 108
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 106
Somatostatin receptor ligands in the treatment of acromegaly 105
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 105
Diagnosis and Treatment of Parasellar Lesions 103
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 102
Regulation Of Prostate Cancer Cell Proliferation By Somatostatin Receptor Activation 101
The role of somatostatin and dopamine D2 receptors in endocrine tumors 101
Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. 100
β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. 98
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 98
Somatostatin receptor pathophysiology in the neuroendocrine system 98
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for 97
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 97
Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: implications for the in vivo visualization during somatostatin receptor scintigraphy. 96
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 92
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 92
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 91
Novel chimeric somatostatin analogs: facts and perspectives 91
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant 90
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas 90
OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells 88
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives 85
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 84
Aggressive and malignant prolactinomas 80
In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 73
Novel Molecular Mechanisms of Resistance to Somatostatin Analog Treatment in Pituitary Adenomas 67
Extraintestinal precoccygeal tumour with endocrine features and its relationship with Currarino syndrome. 65
Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 54
Emerging drugs for the treatment of acromegaly 52
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 51
Body Composition and Bone Status in Relation to Microvascular Damage in Systemic Sclerosis Patients 48
The effect of sodium restriction on iodine prophylaxis: a review 40
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment 38
GH Replacement in the Elderly: Is It Worth It? 37
Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain 36
Octreotide-resistant acromegaly: Challenges and solutions 36
Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective 36
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids 34
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression 32
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. 28
Ultra-short antibiotic prophylaxis guided by preoperative microbiological nasal swabs in endoscopic endonasal skull base surgery 27
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience 25
Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. 24
Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length 19
Modulatory activity of testosterone on growth pattern and IGF-1 levels in vanishing testis syndrome: a case report during 15 years of follow-up 17
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 14
Corrigendum to "Regulation of prostate cancer cell proliferation by somatostatin receptor activation" [Mol. Cell. Endocrinol. 315 (1-2) (2010) 254-262] 12
Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge 12
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 12
Left ventricular mass reduction by a low-sodium diet in treated hypertensive patients 11
Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients 8
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study 7
Cushing's syndrome 7
Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide 6
Corrigendum to {"}Regulation of prostate cancer cell proliferation by somatostatin receptor activation{"} [Mol. Cell. Endocrinol. 315 (1-2) (2010) 254-262] 6
Somatostatin receptors and the associated intracellular machinery: the two sides of the coin 5
Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH/PRL-secreting pituitary tumors 5
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 4
An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report 4
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 3
Editorial: Resistance to Medical Therapy in Pituitary Tumors 3
Challenging diagnosis of resistance to thyroid hormone in a patient with COVID-19, pituitary microadenoma and unusual response to octreotide long-acting release test 3
Skeletal Muscle Evaluation in Patients With Acromegaly 1
Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence? 1
Totale 5.110
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.055
article - articoli 15.608
book - libri 134
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 313
Totale 32.110
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019247 0 0 0 0 0 0 0 0 0 0 133 114
2019/20201.388 62 41 62 105 119 143 189 95 136 242 153 41
2020/2021632 33 52 65 73 60 34 25 76 39 83 57 35
2021/2022709 16 14 80 95 26 56 26 166 51 61 26 92
2022/2023641 56 62 5 47 68 105 18 41 118 11 98 12
2023/2024406 25 56 10 63 30 87 42 24 27 40 2 0
Totale 5.110